Quarterly Result4 May 2026, 05:11 pm
Nath Bio-Genes: FY26 Revenue ₹431.6 Mn, PAT ₹48.6 Mn
AI Summary
Nath Bio-Genes (India) Ltd announced audited financial results for the year ended March 31, 2026. The Board recommended a dividend of ₹2 (20%) per equity share. Mr. Hitesh Rajnikant Purohit was re-appointed as an Independent Director for a second term of five years, effective March 30, 2027. M/s K.P. Sahasrabudhe & Co., Chartered Accountants, were appointed as Internal Auditors for FY 2026-27. The remuneration of Mr. Satish Kagliwal, Managing Director, was increased from ₹66,00,000 to ₹1,44,00,000 per annum, effective January 1, 2026, subject to shareholder approval. Revenue from operations stood at ₹431.6 Mn and Profit from Operations before other income, finance costs and Exceptional Items stood at ₹48.6 Mn.
Key Highlights
- Nath Bio-Genes declares a dividend of ₹2 (20%) per share for FY26.
- Hitesh Rajnikant Purohit re-appointed as Independent Director for five years.
- K.P. Sahasrabudhe & Co. appointed as Internal Auditors for FY 2026-27.
- MD Satish Kagliwal's remuneration increased to ₹1,44,00,000 p.a.
- FY26 Revenue from operations reported at ₹431.6 Mn.